CoChat

A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors

Open access
Gagnon, Lyne, Leduc, Martin, Thibodeau, Jean-Francois, Zhang, Ming-Zhi, Grouix, Brigitte, Sarra-Bournet, Francois, Gagnon, William, Hince, Kathy, Tremblay, Mikaël, Geerts, Lilianne, Kennedy, Christopher R.J., Hébert, Richard L., Gutsol, Alex, Holterman, Chet E., Kamto, Eldjonai, Gervais, Liette, Ouboudinar, Jugurtha, Richard, Jonathan, Felton, Alexandra, Laverdure, Alexandre, Simard, Jean-Christophe, Létourneau, Sylvie, Cloutier, Marie-Pier, Leblond, Francois A., Abbott, Shaun D., Penney, Christopher, Duceppe, Jean-Simon, Zacharie, Boulos, Dupuis, Jocelyn, Calderone, Angelino, Nguyen, Quang T., Harris, Raymond C., Laurin, Pierre · 2018 · The American Journal of Pathology
Cited by 138

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Numerous clinical conditions can lead to organ fibrosis and functional failure. There is a great need for therapies that could effectively target pathophysiological pathways involved in fibrosis. GPR40 and GPR84 are G protein-coupled receptors with free fatty acid ligands and are associated with metabolic and inflammatory disorders. Although GPR40 and GPR84 are involved in diverse physiological processes, no evidence has demonstrated the relevance of GPR40 and GPR84 in fibrosis pathways. Using PBI-4050 (3-pentylbenzeneacetic acid sodium salt), a synthetic analog of a medium-chain fatty acid that displays agonist and antagonist ligand affinity toward GPR40 and GPR84, respectively, we uncovered an antifibrotic pathway involving these receptors. In experiments using Gpr40- and Gpr84-knockout mice in models of kidney fibrosis (unilateral ureteral obstruction, long-term post-acute ischemic injury, and adenine-induced chronic kidney disease), we found that GPR40 is protective and GPR84 is deleterious in these diseases. Moreover, through binding to GPR40 and GPR84, PBI-4050 significantly attenuated fibrosis in many injury contexts, as evidenced by the antifibrotic activity observed in kidney, liver, heart, lung, pancreas, and skin fibrosis models. Therefore, GPR40 and GPR84 may represent promising molecular targets in fibrosis pathways. We conclude that PBI-4050 is a first-in-class compound that may be effective for managing inflammatory and fibrosis-related diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ajpath.2018.01.009

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 138

Metadata

Authors
Gagnon, L., Leduc, M., Thibodeau, J.-F., Zhang, M.-Z., Grouix, B., Sarra-Bournet, F., Gagnon, W., Hince, K., Tremblay, M., Geerts, L., Kennedy, C. R. J., Hébert, R. L., Gutsol, A., Holterman, C. E., Kamto, E., Gervais, L., Ouboudinar, J., Richard, J., Felton, A., Laverdure, A., Simard, J.-C., Létourneau, S., Cloutier, M.-P., Leblond, F. A., Abbott, S. D., Penney, C., Duceppe, J.-S., Zacharie, B., Dupuis, J., Calderone, A., Nguyen, Q. T., Harris, R. C., & Laurin, P.
Venue
The American Journal of Pathology
Publisher
Elsevier BV
Published
2018-05
Volume
188
Issue
5
Pages
1132-1148
ISSN
0002-9440 (ISSN-L)
OpenAlex
W2785444851
Cited by
138
References
5
FWCI
11.10
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.